Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function

The study investigated the effects of a metoprolol-spironolactone combination on cardiac function in 100 patients with coronary heart disease and concurrent heart failure. The research group, treated with both metoprolol and spironolactone, showed significant improvements in cardiac function compared to the control group, which received only spironolactone. Key improvements included reductions in left ventricular end-systolic and end-diastolic diameters, serum brain natriuretic peptide, malondialdehyde, and inflammatory cytokines, alongside increases in left ventricular ejection fraction, superoxide dismutase, cardiac index, and output. The combination therapy also resulted in better cardiac function classification, clinical efficacy, and a lower rate of adverse effects, suggesting it is highly effective and should be considered for broader clinical use.